EGFR and non-small cell lung carcinoma: The CTONG1104/ADJUVANT trial is a phase 3 study that compared the standard cisplatin-vinorelbine chemotherapy to gefitinib, a first-generation EGFR TKI in fully resected stage II to IIIA EGFR mutant NSCLC [12].